{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:13:19Z","timestamp":1793041999442,"version":"4.5.0"},"reference-count":120,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Neurotrophic tropomyosin receptor kinase (NTRK) gene fusion has been identified as an oncogenic driver of various solid tumors, and it is rare in non-smalll cell lung cancer (NSCLC) with a frequency of approximately less than 1%. Next-generation sequencing (NGS) is of priority for detecting NTRK fusions, especially RNA-based NGS. Currently, the tropomyosin receptor kinase (TRK) inhibitors have shown promising efficacy and well tolerance in patients with NTRK fusion-positive solid tumors, regardless of tumor histology. The first-generation TRK inhibitors (larotrectinib and entrectinib) are recommended as the first-line treatment for locally advanced or metastatic NSCLC patients with positive NTRK fusion. However, TRK inhibitor resistance can eventually occur due to on-target or off-target mechanisms. Further studies are under investigation to overcome resistance and improve survival. Interestingly, NTRK fusion might be the mechanism of resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) in NSCLC patients with EGFR mutation. Regarding immunotherapy, the efficacy of immune checkpoint inhibitors in NSCLC patients harboring NTRK fusion has yet to be well described. In this review, we elucidate the function of NTRK genes, summarize the diagnostic techniques for NTRK fusions, and present clinical data for TRK inhibitors; we also discuss potential mechanisms of resistance to TRK inhibitors.<\/jats:p>","DOI":"10.3389\/fonc.2022.864666","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T06:13:26Z","timestamp":1647497606000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":77,"title":["NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance"],"prefix":"10.3389","volume":"12","author":[{"given":"Fangfang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jizong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)31473-8","article-title":"New and Emerging Targeted Treatments in Advanced Non-Small-Cell Lung Cancer","volume":"388","author":"Hirsch","year":"2016","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nature25183","article-title":"The Biology and Management of Non-Small Cell Lung Cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-20-186","article-title":"Emerging Oncogenic Fusions Other Than ALK, ROS1, RET, and NTRK in NSCLC and the Role of Fusions as Resistance Mechanisms to Targeted Therapy","volume":"9","author":"Suda","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12943-018-0810-4","article-title":"The Function and Therapeutic Targeting of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer (NSCLC)","volume":"17","author":"Golding","year":"2018","journal-title":"Mol Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.08.002","article-title":"Recent Advances in Targeting ROS1 in Lung Cancer","volume":"12","author":"Lin","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00206-y","article-title":"Genomic Context of NTRK1\/2\/3 Fusion-Positive Tumours From a Large Real-World Population","volume":"5","author":"Westphalen","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"B8","unstructured":"NCCN Clinical Practice Guidelines in Oncology for Non-Small Cell Lung Cancer2022"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/0888-7543(95)80226-c","article-title":"Rapid Physical Mapping of the Human Trk Protooncogene (NTRK1) to Human Chromosome 1q21-Q22 by P1 Clone Selection, Fluorescence in Situ Hybridization (FISH), and Computer-Assisted Microscopy","volume":"26","author":"Weier","year":"1995","journal-title":"Genomics"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/350158a0","article-title":"Tyrosine Phosphorylation and Tyrosine Kinase Activity of the Trk Proto-Oncogene Product Induced by NGF","volume":"350","author":"Kaplan","year":"1991","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/0888-7543(95)80055-q","article-title":"Cloning and Chromosomal Localization of the Human TRK-B Tyrosine Kinase Receptor Gene (NTRK2)","volume":"25","author":"Nakagawara","year":"1995","journal-title":"Genomics"},{"key":"B12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/0092-8674(91)90628-c","article-title":"The trkB Tyrosine Protein Kinase Is a Receptor for Brain-Derived Neurotrophic Factor and Neurotrophin-3","volume":"66","author":"Klein","year":"1991","journal-title":"Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1159\/000484742","article-title":"Mapping of the Tyrosine Kinase Receptors trkA (NTRK1), trkB (NTRK2) and Trkc(NTRK3) to Human Chromosomes 1q22, 9q22 and 15q25 by Fluorescence in Situ Hybridization","volume":"5","author":"Valent","year":"1997","journal-title":"Eur J Hum Genet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(91)90442-2","article-title":"Trkc, a New Member of the Trk Family of Tyrosine Protein Kinases, is a Receptor for Neurotrophin-3","volume":"66","author":"Lamballe","year":"1991","journal-title":"Cell"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(91)90149-s","article-title":"The Trk Tyrosine Protein Kinase Mediates the Mitogenic Properties of Nerve Growth Factor and Neurotrophin-3","volume":"66","author":"Cordon-Cardo","year":"1991","journal-title":"Cell"},{"key":"B16","doi-asserted-by":"publisher","first-page":"viii5","DOI":"10.1093\/annonc\/mdz383","article-title":"Tropomyosin Receptor Kinase (TRK) Biology and the Role of NTRK Gene Fusions in Cancer","volume":"30","author":"Amatu","year":"2019","journal-title":"Ann Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-006-6010-1","article-title":"Neurotrophin Signaling: Many Exciting Surprises","volume":"63","author":"Ar\u00e9valo","year":"2006","journal-title":"Cell Mol Life Sci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e000023","DOI":"10.1136\/esmoopen-2015-000023","article-title":"NTRK Gene Fusions as Novel Targets of Cancer Therapy Across Multiple Tumour Types","volume":"1","author":"Amatu","year":"2016","journal-title":"ESMO Open"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.127","article-title":"Fusions in Solid Tumours: Diagnostic Strategies, Targeted Therapy, and Acquired Resistance","volume":"14","author":"Schram","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1158\/2159-8290.Cd-14-0765","article-title":"TRKing Down an Old Oncogene in a New Era of Targeted Therapy","volume":"5","author":"Vaishnavi","year":"2015","journal-title":"Cancer Discov"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/319743a0","article-title":"A Human Oncogene Formed by the Fusion of Truncated Tropomyosin and Protein Tyrosine Kinase Sequences","volume":"319","author":"Martin-Zanca","year":"1986","journal-title":"Nature"},{"key":"B22","article-title":"ETV6-NTRK3 Gene Fusions and Trisomy 11 Establish a Histogenetic Link Between Mesoblastic Nephroma and Congenital Fibrosarcoma","volume":"58","author":"Knezevich","year":"1998","journal-title":"Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/ng0298-184","article-title":"A Novel ETV6-NTRK3 Gene Fusion in Congenital Fibrosarcoma","volume":"18","author":"Knezevich","year":"1998","journal-title":"Nat Genet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/s1535-6108(02)00180-0","article-title":"Expression of the ETV6-NTRK3 Gene Fusion as a Primary Event in Human Secretory Breast Carcinoma","volume":"2","author":"Tognon","year":"2002","journal-title":"Cancer Cell"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw042","article-title":"What Hides Behind the MASC: Clinical Response and Acquired Resistance to Entrectinib After ETV6-NTRK3 Identification in a Mammary Analogue Secretory Carcinoma (MASC)","volume":"27","author":"Drilon","year":"2016","journal-title":"Ann Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3352","article-title":"Oncogenic and Drug-Sensitive NTRK1 Rearrangements in Lung Cancer","volume":"19","author":"Vaishnavi","year":"2013","journal-title":"Nat Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/po.18.00037","article-title":"Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion","volume":"2018","author":"Farago","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2019.09.004","article-title":"Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer","volume":"21","author":"Xia","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0118-3","article-title":"Molecular Characterization of Cancers With NTRK Gene Fusions","volume":"32","author":"Gatalica","year":"2019","journal-title":"Mod Pathol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-19-3165","article-title":"TRK Fusions Are Enriched in Cancers With Uncommon Histologies and the Absence of Canonical Driver Mutations","volume":"26","author":"Rosen","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/po.18.00183","article-title":"Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics","volume":"2018","author":"Okamura","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/po.20.00250","article-title":"NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome","volume":"1","author":"Zhao","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920975613","article-title":"A Systematic Review and Meta-Analysis of Neurotrophic Tyrosine Receptor Kinase Gene Fusion Frequencies in Solid Tumors","volume":"12","author":"Forsythe","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1172\/jci120787","article-title":"Oncogenic TRK Fusions Are Amenable to Inhibition in Hematologic Malignancies","volume":"128","author":"Taylor","year":"2018","journal-title":"J Clin Invest"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000000911","article-title":"Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions","volume":"41","author":"Hechtman","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13757","article-title":"Genomic Characteristics of Driver Genes in Chinese Patients With Non-Small Cell Lung Cancer","volume":"12","author":"Si","year":"2021","journal-title":"Thorac Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26260","article-title":"Comprehensive Genomic Profiling Identifies Novel NTRK Fusions in Neuroendocrine Tumors","volume":"9","author":"Sigal","year":"2018","journal-title":"Oncotarget"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.22.6993","article-title":"Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK","volume":"27","author":"Shaw","year":"2009","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.44.1477","article-title":"RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non-Small-Cell Lung Cancer","volume":"30","author":"Wang","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.35.6345","article-title":"ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers","volume":"30","author":"Bergethon","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1097\/01.JTO.0000473485.38553.f0","article-title":"Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer","volume":"10","author":"Farago","year":"2015","journal-title":"J Thorac Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.1038\/ncomms5846","article-title":"The Landscape of Kinase Fusions in Cancer","volume":"5","author":"Stransky","year":"2014","journal-title":"Nat Commun"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4333","article-title":"Mutational Landscape of Metastatic Cancer Revealed From Prospective Clinical Sequencing of 10,000 Patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1200\/po.17.00084","article-title":"Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data","volume":"2017","author":"Middha","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41379-019-0324-7","article-title":"NTRK Fusion Detection Across Multiple Assays and 33,997 Cases: Diagnostic Implications and Pitfalls","volume":"33","author":"Solomon","year":"2020","journal-title":"Mod Pathol"},{"key":"B46","unstructured":"Foundation Medicine FoundationOne CDx"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1158\/2159-8290.Cd-15-0940","article-title":"Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer","volume":"6","author":"Russo","year":"2016","journal-title":"Cancer Discov"},{"key":"B49","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nrg3117","article-title":"Repetitive DNA and Next-Generation Sequencing: Computational Challenges and Solutions","volume":"13","author":"Treangen","year":"2011","journal-title":"Nat Rev Genet"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.10.156","article-title":"Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC","volume":"16","author":"Li","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-19-0225","article-title":"High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas With No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden","volume":"25","author":"Benayed","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2017.127","article-title":"Recurrent EML4-NTRK3 Fusions in Infantile Fibrosarcoma and Congenital Mesoblastic Nephroma Suggest a Revised Testing Strategy","volume":"31","author":"Church","year":"2018","journal-title":"Mod Pathol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1097\/pai.0000000000000360","article-title":"Detecting Gene Rearrangements in Patient Populations Through a 2-Step Diagnostic Test Comprised of Rapid IHC Enrichment Followed by Sensitive Next-Generation Sequencing","volume":"25","author":"Murphy","year":"2017","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3729","article-title":"Anchored Multiplex PCR for Targeted Next-Generation Sequencing","volume":"20","author":"Zheng","year":"2014","journal-title":"Nat Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz204","article-title":"ESMO Recommendations on the Standard Methods to Detect NTRK Fusions in Daily Practice and Clinical Research","volume":"30","author":"Marchi\u00f2","year":"2019","journal-title":"Ann Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00428-018-2411-4","article-title":"Validation of the Oncomine(\u2122) Focus Panel for Next-Generation Sequencing of Clinical Tumour Samples","volume":"473","author":"Williams","year":"2018","journal-title":"Virchows Arch"},{"key":"B57","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jmoldx.2021.09.008","article-title":"Evaluating Targeted Next-Generation Sequencing Assays and Reference Materials for NTRK Fusion Detection","volume":"24","author":"Bormann Chung","year":"2022","journal-title":"J Mol Diagn"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-19-1324","article-title":"Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel","volume":"25","author":"Willis","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B59","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s10020-021-00331-1","article-title":"Liquid Biopsy as an Option for Predictive Testing and Prognosis in Patients With Lung Cancer","volume":"27","author":"Qvick","year":"2021","journal-title":"Mol Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000001062","article-title":"Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors","volume":"42","author":"Rudzinski","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/his.13666","article-title":"Evaluation of Pan-TRK Immunohistochemistry in Infantile Fibrosarcoma, Lipofibromatosis-Like Neural Tumour and Histological Mimics","volume":"73","author":"Hung","year":"2018","journal-title":"Histopathology"},{"key":"B62","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/PAS.0b013e318231542a","article-title":"Mammary Analog Secretory Carcinoma of Salivary Gland Origin With the ETV6 Gene Rearrangement by FISH: Expanded Morphologic and Immunohistochemical Spectrum of a Recently Described Entity","volume":"36","author":"Connor","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-15-0443","article-title":"An Oncogenic NTRK Fusion in a Patient With Soft-Tissue Sarcoma With Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101","volume":"5","author":"Doebele","year":"2015","journal-title":"Cancer Discov"},{"key":"B64","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/pas.0000000000000537","article-title":"Mammary Analogue Secretory Carcinoma of Salivary Glands: Molecular Analysis of 25 ETV6 Gene Rearranged Tumors With Lack of Detection of Classical ETV6-NTRK3 Fusion Transcript by Standard RT-PCR: Report of 4 Cases Harboring ETV6-X Gene Fusion","volume":"40","author":"Sk\u00e1lov\u00e1","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2018-205679","article-title":"Testing Algorithm for Identification of Patients With TRK Fusion Cancer","volume":"72","author":"Penault-Llorca","year":"2019","journal-title":"J Clin Pathol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1097\/jto.0000000000000444","article-title":"ALK Testing in Lung Adenocarcinoma: Technical Aspects to Improve FISH Evaluation in Daily Practice","volume":"10","author":"Martin","year":"2015","journal-title":"J Thorac Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2019.03.008","article-title":"Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit From Tyrosine Kinase (TRK) Inhibitor Therapy","volume":"21","author":"Hsiao","year":"2019","journal-title":"J Mol Diagn"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200007000-00005","article-title":"Molecular Detection of the ETV6-NTRK3 Gene Fusion Differentiates Congenital Fibrosarcoma From Other Childhood Spindle Cell Tumors","volume":"24","author":"Bourgeois","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000000487","article-title":"Secretory Breast Carcinoma: A Histopathologic and Genomic Spectrum Characterized by a Joint Specific ETV6-NTRK3 Gene Fusion","volume":"39","author":"Del Castillo","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-nb2019-047","article-title":"Combating Acquired TRK Inhibitor Resistance","volume":"9","year":"2019","journal-title":"Cancer Discov"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0542-z","article-title":"Resistance to TRK Inhibition Mediated by Convergent MAPK Pathway Activation","volume":"25","author":"Cocco","year":"2019","journal-title":"Nat Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1044-x","article-title":"Larotrectinib: First Global Approval","volume":"79","author":"Scott","year":"2019","journal-title":"Drugs"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy539","article-title":"Larotrectinib in Adult Patients With Solid Tumours: A Multi-Centre, Open-Label, Phase I Dose-Escalation Study","volume":"30","author":"Hong","year":"2019","journal-title":"Ann Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30119-0","article-title":"Larotrectinib for Paediatric Solid Tumours Harbouring NTRK Gene Fusions: Phase 1 Results From a Multicentre, Open-Label, Phase 1\/2 Study","volume":"19","author":"Laetsch","year":"2018","journal-title":"Lancet Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30856-3","article-title":"Larotrectinib in Patients With TRK Fusion-Positive Solid Tumours: A Pooled Analysis of Three Phase 1\/2 Clinical Trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1200\/po.21.00089","article-title":"Impact of Disease Evolution on Efficacy Outcomes From Larotrectinib in Patients With Locally Advanced or Metastatic Tropomyosin Receptor Kinase Fusion-Positive Solid Tumors","volume":"5","author":"Bokemeyer","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113246","article-title":"Larotrectinib Versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis","volume":"12","author":"Italiano","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0641","article-title":"Antitumor Activity of Larotrectinib in Esophageal Carcinoma With NTRK Gene Amplification","volume":"25","author":"Hempel","year":"2020","journal-title":"Oncologist"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2021.100734","article-title":"Quality of Life in Adult and Pediatric Patients With Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib","volume":"45","author":"Kummar","year":"2021","journal-title":"Curr Probl Cancer"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01177-y","article-title":"Entrectinib: First Global Approval","volume":"79","author":"Al-Salama","year":"2019","journal-title":"Drugs"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-20-2771","article-title":"FDA Approval Summary: Entrectinib for the Treatment of NTRK Gene Fusion Solid Tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30691-6","article-title":"Entrectinib in Patients With Advanced or Metastatic NTRK Fusion-Positive Solid Tumours: Integrated Analysis of Three Phase 1-2 Trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100072","article-title":"Intrapatient Comparisons of Efficacy in a Single-Arm Trial of Entrectinib in Tumour-Agnostic Indications","volume":"6","author":"Krebs","year":"2021","journal-title":"ESMO Open"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa052","article-title":"Entrectinib, a TRK\/ROS1 Inhibitor With Anti-CNS Tumor Activity: Differentiation From Other Inhibitors in its Class Due to Weak Interaction With P-Glycoprotein","volume":"22","author":"Fischer","year":"2020","journal-title":"Neuro Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107994","article-title":"Inhibition of MEK1\/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer","volume":"32","author":"Vaishnavi","year":"2020","journal-title":"Cell Rep"},{"key":"B86","doi-asserted-by":"publisher","first-page":"viii36","DOI":"10.1093\/annonc\/mdz385","article-title":"Tumour Response to TRK Inhibition in a Patient With Pancreatic Adenocarcinoma Harbouring an NTRK Gene Fusion","volume":"30","author":"O'Reilly","year":"2019","journal-title":"Ann Oncol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS18-CT127","article-title":"Phase I and Expanded Access Experience of LOXO-195 (BAY 2731954), a Selective Next-Generation TRK Inhibitor (TRKi)","volume":"79","author":"Hyman","year":"2019","journal-title":"Cancer Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-17-0507","article-title":"A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients With TRK Fusion-Positive Solid Tumors","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.7022","article-title":"Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib","volume":"19","author":"Florou","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1101\/mcs.a006109","article-title":"Mechanisms of Targeted Therapy Resistance in a Pediatric Glioma Driven by ETV6-NTRK3 Fusion","volume":"7","author":"Keddy","year":"2021","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"B91","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jchromb.2019.05.026","article-title":"Bioanalytical Assay for the Novel TRK Inhibitor Selitrectinib in Mouse Plasma and Tissue Homogenates Using Liquid Chromatography-Tandem Mass Spectrometry","author":"Sparidans","year":"2019","journal-title":"J Chromatogr B Analyt Technol BioMed Life Sci"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-20-0705","article-title":"ABCB1 and ABCG2 Restrict Brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib","volume":"20","author":"Li","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-20-0571","article-title":"TRK xDFG Mutations Trigger a Sensitivity Switch From Type I to II Kinase Inhibitors","volume":"11","author":"Cocco","year":"2021","journal-title":"Cancer Discov"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220938849","article-title":"Larotrectinib Followed by Selitrectinib in a Novel DCTN1-NTRK1 Fusion Undifferentiated Pleomorphic Sarcoma","volume":"27","author":"Goh","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00712","article-title":"Discovery of the Next-Generation Pan-TRK Kinase Inhibitors for the Treatment of Cancer","volume":"64","author":"Liu","year":"2021","journal-title":"J Med Chem"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01539","article-title":"Discovery of Next-Generation Tropomyosin Receptor Kinase Inhibitors for Combating Multiple Resistance Associated With Protein Mutation","volume":"64","author":"Zhuo","year":"2021","journal-title":"J Med Chem"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-18-0484","article-title":"Repotrectinib (TPX-0005) Is a Next-Generation ROS1\/TRK\/ALK Inhibitor That Potently Inhibits ROS1\/TRK\/ALK Solvent- Front Mutations","volume":"8","author":"Drilon","year":"2018","journal-title":"Cancer Discov"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-21-0632","article-title":"Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations","volume":"20","author":"Murray","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-19-2777","article-title":"Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Na\u00efve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer","volume":"26","author":"Yun","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2020.122098","article-title":"Bioanalytical Assay for the New-Generation ROS1\/TRK\/ALK Inhibitor Repotrectinib in Mouse Plasma and Tissue Homogenate Using Liquid Chromatography-Tandem Mass Spectrometry","volume":"1144","author":"Li","year":"2020","journal-title":"J Chromatogr B Analyt Technol BioMed Life Sci"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13111761","article-title":"ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1\/TRK\/ALK Inhibitor Repotrectinib, While OATP1A\/1B, ABCG2, and CYP3A Limit Its Oral Availability","volume":"13","author":"Li","year":"2021","journal-title":"Pharmaceutics"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2019-442","article-title":"Repotrectinib, a Next Generation Trk Inhibitor, Overcomes Trk Resistance Mutations Including Solvent Front, Gatekeeper and Compound Mutations","volume":"79","author":"Drilon","year":"2019","journal-title":"Cancer Res"},{"key":"B103","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1038\/s41467-019-11496-z","article-title":"The New-Generation Selective ROS1\/NTRK Inhibitor DS-6051b Overcomes Crizotinib Resistant ROS1-G2032R Mutation in Preclinical Models","volume":"10","author":"Katayama","year":"2019","journal-title":"Nat Commun"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-20-1630","article-title":"U.S. Phase I First-In-Human Study of Taletrectinib (DS-6051b\/AB-106), a ROS1\/TRK Inhibitor, in Patients With Advanced Solid Tumors","volume":"26","author":"Papadopoulos","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2020.100108","article-title":"Efficacy of Taletrectinib (AB-106\/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. And Japan Phase 1 Studies","volume":"2","author":"Ou","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25263","article-title":"Safety and Pharmacokinetics of DS-6051b in Japanese Patients With non-Small Cell Lung Cancer Harboring ROS1 Fusions: A Phase I Study","volume":"9","author":"Fujiwara","year":"2018","journal-title":"Oncotarget"},{"key":"B107","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s42003-020-01508-w","article-title":"NTRK Kinase Domain Mutations in Cancer Variably Impact Sensitivity to Type I and Type II Inhibitors","volume":"3","author":"Somwar","year":"2020","journal-title":"Commun Biol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-17-1623","article-title":"Foretinib Overcomes Entrectinib Resistance Associated With the NTRK1 G667C Mutation in NTRK1 Fusion-Positive Tumor Cells in a Brain Metastasis Model","volume":"24","author":"Nishiyama","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/s41467-021-21396-w","article-title":"Gilteritinib Overcomes Lorlatinib Resistance in ALK-Rearranged Cancer","volume":"12","author":"Mizuta","year":"2021","journal-title":"Nat Commun"},{"key":"B110","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1200\/po.19.00287","article-title":"Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of NTRK1","volume":"4","author":"Hemming","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.05.027","article-title":"Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions Are Rare But Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors","volume":"13","author":"Schrock","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-18-1022","article-title":"Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition With Osimertinib and BLU-667 for Acquired RET Fusion","volume":"8","author":"Piotrowska","year":"2018","journal-title":"Cancer Discov"},{"key":"B113","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.cllc.2018.07.008","article-title":"Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor","volume":"19","author":"Helman","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.12.017","article-title":"Durable Clinical Response to Crizotinib in IRF2BP2-NTRK1 Non-Small-Cell Lung Cancer","volume":"20","author":"Wang","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-20-0522","article-title":"Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors","volume":"10","author":"Sha","year":"2020","journal-title":"Cancer Discov"},{"key":"B116","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-019-0738-1","article-title":"Mismatch Repair Deficiency\/Microsatellite Instability-High as a Predictor for Anti-PD-1\/PD-L1 Immunotherapy Efficacy","volume":"12","author":"Zhao","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-14-0983","article-title":"PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-18-3126","article-title":"Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF\/KRAS Are Enriched for Targetable Kinase Fusions","volume":"79","author":"Cocco","year":"2019","journal-title":"Cancer Res"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0212-1","article-title":"Prevalence of Recurrent Oncogenic Fusion in Mismatch Repair-Deficient Colorectal Carcinoma With Hypermethylated MLH1 and Wild-Type BRAF and KRAS","volume":"32","author":"Wang","year":"2019","journal-title":"Mod Pathol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12890-021-01490-x","article-title":"A Novel NCOR2-NTRK1 Fusion Detected in a Patient of Lung Adenocarcinoma and Response to Larotrectinib: A Case Report","volume":"21","author":"Zhang","year":"2021","journal-title":"BMC Pulm Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.864666\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T06:13:31Z","timestamp":1647497611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.864666\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,17]]},"references-count":120,"alternative-id":["10.3389\/fonc.2022.864666"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.864666","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,17]]},"article-number":"864666"}}